Brain-Selective Risperidone Prodrug: Revised Research Proposal

Dihydropyridine-Based Chemical Delivery System for P-glycoprotein Evasion

Executive Summary

The Problem: Risperidone causes hyperprolactinemia in 70–100% of patients through D2 receptor blockade at the pituitary gland. Current management strategies — dose reduction, switching, aripiprazole augmentation, dopamine agonists — all carry significant risks including psychiatric destabilization, polypharmacy burden, or psychosis exacerbation. No approved therapy exists for antipsychotic-induced hyperprolactinemia.

The Key Insight: The pituitary gland lies outside the blood-brain barrier (circumventricular organ). The therapeutic target (striatal D2 receptors) lies inside the BBB. A prodrug that preferentially delivers risperidone to the brain while minimizing peripheral exposure would eliminate hyperprolactinemia without compromising antipsychotic efficacy.

The Updated Approach: Following expert consultation with the University of Eastern Finland (LAT1 prodrug research group), the original LAT1-based strategy was found to be impractical due to risperidone’s size exceeding LAT1 transport capacity and P-glycoprotein (P-gp) mediated efflux being the primary barrier. The revised strategy uses a dihydropyridine–pyridinium chemical delivery system (DHP-CDS) to achieve brain-selective risperidone delivery through P-gp evasion and oxidative brain lock-in.

Scientific Rationale

Why Risperidone Has Poor Brain Selectivity

Risperidone’s brain distribution is primarily limited by P-glycoprotein (P-gp), an efflux transporter at the BBB:

• mdr1a knockout mice show 10-fold higher brain concentrations of risperidone compared to wild-type animals (Wang et al., 2006; Kirschbaum et al., 2008)
• Plasma concentrations remain unchanged — the difference is entirely due to P-gp efflux at the BBB
• This creates a paradoxical situation: risperidone has disproportionately high pituitary exposure (outside BBB, freely accessible) relative to striatal exposure (inside BBB, limited by P-gp)

This P-gp-driven pharmacokinetic imbalance is the root cause of risperidone’s severe hyperprolactinemia profile.

Why LAT1 Prodrug Delivery Is Not Viable for Risperidone

Initial evaluation considered LAT1-mediated transport across the BBB. Expert assessment (Prof. Mikko Gynther, University of Eastern Finland — a leading authority on LAT1 prodrugs) identified critical limitations:

1. Size limitation: Risperidone (~410 Da) is already at the upper threshold of LAT1 substrate size. An amino acid conjugate would inhibit LAT1 rather than be transported.
2. Hepatic rerouting: The conjugate would likely be an OAT/OATP substrate, redirected to the liver.
3. P-gp dual barrier: Even if the prodrug entered endothelial cells, release of risperidone there would result in immediate P-gp-mediated efflux back into the bloodstream.

The Revised Strategy: Dihydropyridine Chemical Delivery System

The DHP-CDS approach (Bodor et al., published in Science, 1981) uses a fundamentally different mechanism:

DHP-Risperidone (lipophilic, uncharged)
         │
    Passive BBB crossing (no transporter needed)
    P-gp does not recognize modified compound
         │
    ┌────┴────────────────────────────┐
    │                                  │
 PERIPHERY                          BRAIN
    │                                  │
 Oxidation to                    Oxidation to
 Pyridinium⁺-Risp               Pyridinium⁺-Risp
    │                                  │
 Charged → rapid                 Charged → TRAPPED
 renal elimination               Cannot cross BBB
    │                                  │
 LOW peripheral                  ACCUMULATION
 risperidone levels              Slow release of
    │                            risperidone in
 Pituitary sees                  parenchyma
 LOW levels                           │
    │                            HIGH striatal
 → Minimal D2 blockade           D2 occupancy
 → No hyperprolactinemia         → Antipsychotic effect

Mechanism of Action — Step by Step

1. Prodrug design: Risperidone is conjugated at the piperidine nitrogen with a dihydropyridine (DHP) promoiety. This eliminates the basic nitrogen character, increases lipophilicity, and alters the molecular geometry.

2. BBB crossing: The lipophilic DHP-prodrug crosses the BBB by passive diffusion. No transporter is required — eliminating size limitations. The structural modification likely disrupts P-gp substrate recognition.

3. Oxidative lock-in: NAD(P)⁺-dependent oxidoreductases convert the dihydropyridine to its pyridinium form throughout the body. The resulting charged pyridinium–risperidone conjugate is:

   • In the periphery: rapidly eliminated via renal excretion (charged, hydrophilic)
   • In the brain: physically trapped behind the BBB (charged species cannot cross)

4. Brain-selective release: The trapped pyridinium conjugate serves as a reservoir, slowly releasing unmodified risperidone within the brain parenchyma.

5. Pituitary sparing: The pituitary gland, located outside the BBB, is exposed only to the low peripheral concentrations of free risperidone. D2 receptor blockade at lactotrophs is minimized.

Advantages Over the LAT1 Approach

Validation & Precedent

Risk Assessment (Revised)

No Red Flags: No Risk 4 or 5 assumptions. No late high-risk elements. Go/No-Go achievable in 6 months.

Development Plan

Phase 1: In Vitro Validation (Months 1–3)

Experiment 1.1: DHP-Risperidone Synthesis - Conjugation at piperidine nitrogen with DHP promoiety - Characterization (NMR, MS, purity)

Experiment 1.2: Plasma Stability - Incubation in human plasma, HPLC monitoring - Success: DHP-prodrug t½ > 2 hours in plasma

Experiment 1.3: P-gp Substrate Assessment - Bidirectional transport in Caco-2 or MDCK-MDR1 cells - Success: Efflux ratio < 2 (indicating P-gp evasion)

Experiment 1.4: Brain Homogenate Conversion - Incubation with rat brain homogenate - Success: Oxidation to pyridinium > 50% in 2h; risperidone release detectable

→ GO/NO-GO DECISION #1

Phase 2: In Vivo Proof-of-Concept (Months 4–6)

Experiment 2.1: Brain/Plasma Ratio in Rodents - PK study in rats: DHP-risperidone vs. risperidone - Success: Brain/plasma ratio significantly improved (target: > 3-fold increase)

Experiment 2.2: Prolactin Biomarker (CRITICAL) - Serum prolactin measurement: DHP-risperidone vs. risperidone at equieffective antipsychotic doses - Success: Significantly lower prolactin elevation with DHP-risperidone - This is the ultimate proof of concept

Experiment 2.3: Behavioral Efficacy - Catalepsy or amphetamine-induced hyperlocomotion assay - Success: Comparable antipsychotic effect to risperidone

→ GO/NO-GO DECISION #2

Phase 3: Optimization (Months 7–12)

• Linker/promoiety optimization
• Toxicology screening
• PK/PD modeling
• Scale-up synthesis

Budget Estimate (Phase 1–2: Proof-of-Concept)

Competitive Landscape

No direct competitors identified. See separate Competitive Landscape Analysis for full details.

Key differentiators: - First brain-selective antipsychotic using DHP-CDS technology - Platform potential — applicable to other P-gp substrate antipsychotics - Clear regulatory path — 505(b)(2) leveraging existing risperidone data - No competing brain-selective antipsychotics in development - KarXT/Cobenfy (muscarinic) avoids prolactin but uses entirely different mechanism; DHP-risperidone preserves proven D2 antagonist efficacy

Team Requirements & Potential Collaborators

Essential expertise: - Medicinal chemist (DHP-prodrug synthesis, N-conjugation chemistry) - Pharmacologist (P-gp assays, in vivo PK, prolactin biomarkers) - CNS drug delivery specialist

Potential academic partners: - Groups with DHP-CDS experience (prodrug chemistry) - Groups with P-gp/BBB transport expertise - Groups with antipsychotic pharmacology focus

Pharma partners (as previously identified): - Lundbeck (CNS focus, external innovation program) - Janssen (original risperidone developer) - Otsuka (aripiprazole maker, understands prolactin problem)

Regulatory Strategy

505(b)(2) / EMA Hybrid Application

Unchanged from previous assessment. The approach leverages existing risperidone safety and efficacy data: - Reduced preclinical package (focus on prodrug-specific toxicology) - Potentially smaller Phase 1 (safety of DHP promoiety + PK) - Timeline: 2–3 years faster than new chemical entity pathway

IP Considerations

• DHP-CDS method: Original Bodor patents expired (1980s). Methodology is public domain.
• DHP-risperidone compound: Novel — no prior publications or patents identified (search: Feb 2026)
• Patentable aspects: Specific compound structure, brain/peripheral ratio data, method of treating schizophrenia with reduced prolactin elevation
• Recommendation: File provisional patent upon proof-of-concept data generation

References

1. Bodor N, Simpkins JW. (1983) “Brain-specific delivery of dopamine with a dihydropyridine ⇌ pyridinium salt type redox delivery system.” J Med Chem 26:584–589
2. Bodor N, Buchwald P. (2000) “Targeting drugs to the brain by redox chemical delivery systems.” Pharmacol Ther 87:165–198
3. Bodor N, Farag HH, Brewster ME. (1981) “Site-specific, sustained release of drugs to the brain.” Science 214:1370–1372
4. Wang JS et al. (2006) “Risperidone and paliperidone inhibit P-glycoprotein activity in vitro.” Neuropsychopharmacology 31:1–9 (P-gp knockout: 10x brain increase)
5. Kirschbaum KM et al. (2008) “Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.” Behav Brain Res 188:298–303
6. Wang Y et al. (2022) “Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies.” Front Psychiatry PMC9121093
7. Rautio J et al. (2025) “Prodrugs and their activation mechanisms for brain drug delivery.” RSC Med Chem PMC11740913
8. Bohn K et al. (2017) “Dual Modulation of Human P-Glycoprotein and ABCG2 with Prodrug Dimers of Paliperidone.” Mol Pharm 14:1107–1119
9. Emmert D et al. (2014) “Reversible Dimers of Quetiapine Inhibit P-gp at the BBB.” ACS Chem Neurosci 5:305–317
10. Scanlan TS et al. (2017) “Targeting fatty-acid amide hydrolase with prodrugs for CNS-selective therapy.” ACS Chem Neurosci 8:2468–2476
11. Gynther M et al. (2008) “Large neutral amino acid transporter enables brain drug delivery via prodrugs.” J Med Chem
12. Huttunen KM et al. (2019) “LAT1-Utilizing Prodrugs Improve Delivery into Neurons, Astrocytes and Microglia.” Sci Rep

Document Version: 2.0 — Revised following expert consultation Created: February 2026 Status: Revised Research Proposal — Seeking Collaboration/Funding Confidential — For Discussion Purposes Only